Abstract
Atrial fibrillation (AF) is the most common sustained rhythm disturbance, increasing prevalence with age, in particular in patients with cardiovascular disease. On the other hand, a subset of patients with AF being <60 years old and no evidence of underlying cardiovascular disease, and laboratory tests including thyroid function, echocardiography and exercise” test is well described. This is the called lone AF, where there is no previous cardiovascular disease, and the etiology is unknown. However, in the last years, some new factors have been related to play a role or be associated to incident AF. Conditions such as obesity, sleep apnea, alcohol intake, exercise practice, or genetic factors are associated with the development of this common arrhythmia and make the exclusion diagnosis of lone AF more complicated. The aim of the present manuscript is to provide an overview of these new risk factors for AF, which are becoming of special interest in the study of this common arrhythmia.
Keywords: Atrial fibrillation, obesity, obstructive sleep apnoea, diagnosis.
Current Pharmaceutical Design
Title:Lone Atrial Fibrillation- A Diagnosis of Exclusion
Volume: 21 Issue: 5
Author(s): Antonio Tello-Montoliu, Diana Hernández-Romero, Marianela Sanchez-Martínez, Mariano Valdes and Francisco Marín
Affiliation:
Keywords: Atrial fibrillation, obesity, obstructive sleep apnoea, diagnosis.
Abstract: Atrial fibrillation (AF) is the most common sustained rhythm disturbance, increasing prevalence with age, in particular in patients with cardiovascular disease. On the other hand, a subset of patients with AF being <60 years old and no evidence of underlying cardiovascular disease, and laboratory tests including thyroid function, echocardiography and exercise” test is well described. This is the called lone AF, where there is no previous cardiovascular disease, and the etiology is unknown. However, in the last years, some new factors have been related to play a role or be associated to incident AF. Conditions such as obesity, sleep apnea, alcohol intake, exercise practice, or genetic factors are associated with the development of this common arrhythmia and make the exclusion diagnosis of lone AF more complicated. The aim of the present manuscript is to provide an overview of these new risk factors for AF, which are becoming of special interest in the study of this common arrhythmia.
Export Options
About this article
Cite this article as:
Tello-Montoliu Antonio, Hernández-Romero Diana, Sanchez-Martínez Marianela, Valdes Mariano and Marín Francisco, Lone Atrial Fibrillation- A Diagnosis of Exclusion, Current Pharmaceutical Design 2015; 21 (5) . https://dx.doi.org/10.2174/1381612820666140825142206
DOI https://dx.doi.org/10.2174/1381612820666140825142206 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pulmonary Arterial Hypertension: Need to Treat
Inflammation & Allergy - Drug Targets (Discontinued) The Role of the Osteoprotegerin/RANKL/RANK System in Diabetic Vascular Disease
Current Medicinal Chemistry Stem Cell Therapies
Recent Patents on Regenerative Medicine Synthesis, Characterization and Evaluation of Gemfibrozil-Stilbene Hybrid as Antioxidant Agent
Letters in Drug Design & Discovery Human Embryonic and Induced Pluripotent Stem Cells in Cardiovascular Drug Discovery: Patents and Patented Uses
Recent Patents on Cardiovascular Drug Discovery Bronchiolitis Care in the Hospital
Reviews on Recent Clinical Trials Management of Chemotherapy Induced Cardiomyopathy
Current Cardiology Reviews Editorial: Cardiovascular Disease Mortality Rates are Plateauing in Certain Age Groups and Regions. Can we Keep them Declining?
Current Vascular Pharmacology Imaging and Laboratory Biomarkers in Cardiovascular Disease
Current Pharmaceutical Design Molecular Aspects of Modulation of L-type Calcium Channels by Protein Kinase C
Current Molecular Pharmacology Neutrophil Gelatinase-Associated Lipocalin (NGAL) as a New Biomarker for Non – Acute Kidney Injury (AKI) Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Therapeutic Potential of Targeting Protease Activated Receptors in Cardiovascular Diseases
Current Pharmaceutical Design Walnut Extract Inhibits the Fibrillization of Amyloid Beta-Protein, and also Defibrillizes its Preformed Fibrils
Current Alzheimer Research Novel Approaches in the Treatment of Antipsychotic-Induced Hyperprolactinemia: The Role of Partial Agonists of D2 Dopaminergic Receptors
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Nitric Oxide Synthases and Their Natural Inhibitors
Current Enzyme Inhibition Vascular Risk Factors and Alzheimer’s Disease Pathogenesis: Are Conventional Pharmacological Approaches Protective For Cognitive Decline Progression?
CNS & Neurological Disorders - Drug Targets The Effects of Newer Beta-Adrenoceptor Antagonists on Vascular Function in Cardiovascular Disease
Current Vascular Pharmacology Metabolic Syndrome Components in Murine Models
Endocrine, Metabolic & Immune Disorders - Drug Targets Weight Loss in Obesity and Metabolic Syndrome
Current Hypertension Reviews S100A1: Structure, Function, and Therapeutic Potential
Current Chemical Biology